JIUQUAN, China, Nov. 1, 2021
/PRNewswire/ -- Qilian International Holding Group Limited
(Nasdaq: QLI) (the "Company"), a China-based
pharmaceutical and chemical products manufacturer, announced
that recently, through its subsidiary Gansu Qilianshan
Pharmaceutical Co., Ltd. ("Gansu QLS"), the Company
donated Gan Di Xin®, its self-developed antitussive and
expectorant medicine, and 75% alcohol disinfectant, with an
aggregate value of more than RMB500,000 to the government of Suzhou District,
Jiuquan City to help control the spread of local COVID-19
epidemic newly reported in October.
Since October 2021, new cases of
COVID-19 infection have been reported in several provinces in
China, including Inner Mongolia,
Shaanxi, Gansu and Ningxia. The Company took immediate
actions and donated its innovative products, Gan Di
Xin® and 75% alcohol disinfectant to the
government of Suzhou District, Jiuquan City, to assist local
governments in controlling the spread of COVIDI-19 and take its
social responsibilities to protect the health of local people.
The Company's product Gan Di Xin®, an enhanced type of
compound licorice tablet, is an innovative antitussive and
expectorant medicine made from raw licorice materials. Gan Di
Xin® is independently developed by Gansu QLS protected by
patents, and is a nationally well-known chemical preparation
product, Gansu famous brand
product, and the most influential innovative product of the
Company. Gan Di Xin®'s main ingredient, glycyrrhetinic acid, could
have a positive effect on the antiviral function of coronavirus,
according to a research article published in Taylor &
Francis.
The Company donated RMB2 million
worth of drugs to the affected areas in Hubei back in the early days of the COVID-19
outbreak. In February 2020, just few
months after the COVID-19 outbreak started, the Company donated a
large amount of Gan Di Xin® to the hardest-hit
areas in Hubei such as Huanggang,
Xiaogan and Yingcheng to help local hospitals treat infected
people.
Mr. Zhanchang Xin, Chairman and CEO of the Company, commented,
"The global COVID-19 pandemic is still ongoing and spreading
rapidly. As a pharmaceutical company, we take the responsibility to
help fight the local epidemic and protect the public health."
About Qilian International Holding Group Limited
Qilian International Holding Group Limited, headquartered
in Gansu, China, is a
pharmaceutical and chemical products manufacturer in China. It
focuses on the development, manufacture, marketing and sale of
licorice products, oxytetracycline products, traditional Chinese
medicine derivatives product, heparin product, sausage casings, and
fertilizers. The Company's products are sold in more than 20
provinces in China. For more information, visit the company's
website at http://qilianinternational.com/
Forward-Looking Statements
This announcement contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All statements other than statements
of historical fact in this announcement are forward-looking
statements. These forward-looking statements involve known and
unknown risks and uncertainties and are based on current
expectations and projections about future events and financial
trends that the Company believes may affect its financial
condition, results of operations, business strategy, financial
needs and the successful construction of the pig by-product
processing project facility. Investors can identify these
forward-looking statements by words or phrases such as "may,"
"will," "expect," "anticipate," "aim," "estimate," "intend,"
"plan," "believe," "potential," "continue," "is/are likely to" or
other similar expressions. The Company undertakes no obligation to
update forward-looking statements to reflect subsequent occurring
events or circumstances, or changes in its expectations, except as
may be required by law. Although the Company believes that the
expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual
results may differ materially from the anticipated results and
encourages investors to review other factors that may affect its
future results in the Company's registration statement and in its
other filings with the SEC.
For more information, please contact:
Qilian International Holding Group Limited
Email: QLI@qlsyy.net
Related Links
http://ir.qlsyy.net/.
View original
content:https://www.prnewswire.com/news-releases/qilian-international-holding-group-limited-donates-pharmaceutical-products-gan-di-xin-worth-rmb500-000-and-other-materials-to-help-fight-local-covid-19-epidemic-301412750.html
SOURCE Qilian International Holding Group Limited